CYP27A1 Inhibitors

CYP27A1 inhibitors predominantly target the enzymatic activity of CYP27A1, a crucial enzyme in cholesterol metabolism. CYP27A1 is responsible for the 27-hydroxylation of cholesterol, a key step in bile acid synthesis. Inhibitors of CYP27A1, therefore, can significantly impact cholesterol and bile acid homeostasis. GW273297X is a specific inhibitor of CYP27A1, effectively blocking the enzyme's ability to hydroxylate cholesterol. This targeted inhibition is valuable for studying the role of CYP27A1 in cholesterol metabolism and related disorders. Several antifungal agents like Voriconazole, Ketoconazole, Itraconazole, Clotrimazole, and Miconazole are known to inhibit various cytochrome P450 enzymes, including CYP27A1. These inhibitors act by binding to the heme group of the cytochrome P450 enzymes, thus interfering with their catalytic activity.

Other compounds like Orlistat, Anastrozole, and Aminoglutethimide, have been shown to affect CYP27A1 activity. For instance, Orlistat, impacts cholesterol metabolism through its interaction with CYP27A1. Furthermore, compounds like Tranylcypromine and Phenobarbital, though not primarily targeted towards CYP27A1, can modulate its activity due to their broad effects on various cytochrome P450 enzymes. Ritonavir, is another example of a drug with multiple effects, including potential inhibition of CYP27A1.